after you join the study, you are assigned a study number and the computer randomly places you into one of two groups.

one group receives the investigational drug gsk5733584 (dose: 5.8 mg per kilogram of body weight, given by intravenous infusion).

the other group receives the physician’s choice of a standard treatment, which may be one of the following intravenous drugs:

topotecan – 4 mg per square meter,

paclitaxel – 80 mg per square meter,

pembrolizumab (keytruda) – 400 mg,

doxorubicin (caelyx) – 40 mg per square meter,

gemcitabine – 1000 mg per square meter,

bevacizumab (zirabev) – 10 mg per kilogram.

before the first infusion, you undergo a series of tests to document your health status.

these include physical measurements, blood laboratory tests, electrocardiogram (ecg), and imaging scans to evaluate the extent of ovarian cancer.

questionnaires about quality of life and symptoms are also completed.

on the day of the first treatment, the assigned medication is prepared and administered through an intravenous line.

the infusion is performed in a clinical setting under medical supervision.

the dose described in the randomization step is given during this session.

you return for additional infusion visits according to the schedule determined by the study protocol.

at each visit, the same medication and the same dose (based on body surface area or weight) are administered.

the interval between infusions is consistent with standard practice for the selected drug, but exact timing follows the trial’s predefined schedule.

before and after each infusion, vital signs (blood pressure, pulse, temperature) are checked.

blood samples are taken to monitor laboratory values such as blood counts and chemistry.

any side effects are recorded using patient‑reported questionnaires and clinical assessments.

periodic imaging scans are performed to assess tumor size and determine whether the disease is progressing.

the same criteria (recist 1.1) are used throughout the study to ensure consistent evaluation.

if side effects reach a level that requires a change, the study physician may delay the next infusion or reduce the dose.

any modification follows the predefined rules of the trial protocol.

treatment stops when any of the following occurs: disease progression confirmed by imaging, unacceptable toxicity, withdrawal from the study, or completion of the planned number of cycles.

after treatment ends, you continue to be seen at scheduled intervals for safety checks and survival monitoring.

blood tests, imaging, and quality‑of‑life questionnaires are repeated to collect long‑term data.